Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+breast cancer (BC): 5-year analysis of the phase III ExteNET trial

Results

Naziv:	Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+breast cancer (BC): 5-year analysis of the phase III ExteNET trial
Autori :	Jimenez, Martin M; ...; Tomasevic, Zoran M; ...; (broj, koautora 20)
Godina:	2017
Publikacija:	ANNALS OF ONCOLOGY
ISSN:	0923-7534 Annals of Oncology Pretraži identifikator
Tip rezultata:	Konferencijski rad
Kolacija:	vol. 28 str. v43-v43
DOI:	10.1093/annonc/mdx362
WoS-ID:	000411324000078
URI:	https://enauka.gov.rs/handle/123456789/809472
Projekat:	Puma Biotechnology
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	Mp kategorija će biti prikazana naknadno.

4
OpenCitations

Altmetric

Dimensions

Unpaywall

Google Scholar^TM